HighTide Therapeutics Past Earnings Performance
Past criteria checks 0/6
HighTide Therapeutics has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 31.7% annually.
Key information
9.8%
Earnings growth rate
89.3%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | n/a |
| Return on equity | -109.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How HighTide Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -601 | 131 | 393 |
| 31 Mar 24 | 0 | -770 | 134 | 353 |
| 31 Dec 23 | 0 | -939 | 137 | 312 |
| 30 Sep 23 | 0 | -803 | 102 | 269 |
| 30 Jun 23 | 0 | -666 | 67 | 226 |
| 31 Mar 23 | 0 | -428 | 55 | 205 |
| 31 Dec 22 | 0 | -190 | 43 | 183 |
Quality Earnings: 2511 is currently unprofitable.
Growing Profit Margin: 2511 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2511's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2511's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2511 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).
Return on Equity
High ROE: 2511 has a negative Return on Equity (-109.45%), as it is currently unprofitable.